Form 4: 10x Genomics Director Shehnaaz Suliman Reports Acquisition of Class A Common Stock

Director Shehnaaz Suliman reports acquisition of 8,649 shares of 10x Genomics Class A Common Stock through restricted stock units.

Summary

• On June 11, 2024, Shehnaaz Suliman, a director of 10x Genomics, Inc. (TXG), acquired 8,649 shares of Class A Common Stock.
• The acquisition was through restricted stock units (RSUs), each representing a contingent right to receive one share of Class A Common Stock upon vesting.
• The RSUs vest quarterly, with 1/4th vesting on each quarterly anniversary from May 21, 2024, contingent upon continued service.
• Following the transaction, Suliman directly owns 13,259 shares of Class A Common Stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The acquisition of shares by a director is generally viewed as a positive sign, but it's a routine occurrence.

Positives

• The acquisition of shares by a director may signal confidence in the company's future prospects.

Future Outlook

The vesting schedule of the RSUs indicates a continued relationship between the director and the company.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates